CD276 and neoplasm: Furthermore, the anti‐B7‐H3 antibody in the novel immune checkpoint inhibitor B7‐H3‐CD3 bispecific antibody specifically targeted tumor cells, not only by blocking inhibitory signaling pathways to suppress tumor immune evasion and promote T‐cell activation but also by recruiting T cells through the CD3 arm, facilitating the formation of immune synapses and reducing the spatial barrier between T cells and tumor cells, thereby activating T cells.